Genovis’ founder Sarah Fredriksson proposed new Chairperson of the company – Vice President Fredrik Olsson appointed new CEO

Sarah Fredriksson, founder of Genovis, will hand over the reins at the AGM on May 5 to Fredrik Olsson, who will become the new CEO of the company. The Nomination Committee has submitted a new proposal to the AGM and proposes that Sarah Fredriksson be elected to serve as the new Chair of the Board. Sarah Fredriksson will remain in the company with responsibility for the subsidiary GeccoDots.

Genovis' Board has decided to streamline operations to include only the core business, enzyme products that are primarily used in pharmaceutical research and production. The subsidiary GeccoDots will therefore be spun off and will be financed by external funds moving forward. Sarah Fredriksson will work operationally in GeccoDots moving forward, primarily focusing on commercial development and stable financing.

-      “Fredrik Olsson has been with Genovis since 2002 and has helped to build the company. Fredrik holds a degree in engineering and was born in 1971. As Vice President he has mainly worked with business development, marketing and sales. With his strong leadership skills, Fredrik will contribute to Genovis’ continued expansion and commercial development,” says Sarah Fredriksson.

-        “With Sarah Fredriksson chairing the Board, continuity and expertise within the Group are ensured,” says Mikael Lönn, chairman of the Nomination Committee.

Nomination Committee Proposal to Genovis’ Board of Directors:

The Nomination Committee proposes re-election of ordinary members Jacob Engellau, Kenth Petersson, Mikael Lönn and Lena Mårtensson Wernrud.

The Nomination Committee proposes election of Sarah Fredriksson.

Erik Walldén has declined re-election.

The Nomination Committee proposes that Sarah Fredriksson be elected Chairperson of the Board of Directors.

Sarah Fredriksson is active as a board member of SwedNanoTech AB, Sparbankstiftelsen Skåne's Riskkapitalstiftelse and the Wahlgrenska Foundation, as well as GeccoDots AB. From 2007 to 2013 she served as an external director appointed by the government on the Board of Directors of Lund University and from 2000 to 2003 she was a director at EURIS AB.

Sarah Fredriksson has 72,324 shares and 360,000 warrants in the company.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 0046 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00


This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.


About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links